

1 **Title page**

2 To pool or not to pool samples for Sexually Transmitted Infections detection in Men who  
3 have Sex with Men? An evaluation of a new pooling method using the GeneXpert  
4 instrument in West-Africa.

5 **Running Title:** Pooling samples for STI screening in MSM

6 **Authors:**

7 Irith De Baetselier<sup>a#</sup>, Bea Vuylsteke<sup>b</sup>, Issifou Yaya<sup>c</sup>, Anoumou Dagnra<sup>d</sup>, Souba Diandé<sup>e</sup>,  
8 Jeff Yaka<sup>f</sup>, Gérard Kadanga<sup>d</sup>, Issa Traore<sup>g</sup>, Vicky Cuylaerts<sup>a</sup>, Hilde Smet<sup>a</sup>, Elias Dah<sup>c,g,h</sup>,  
9 Ephrem Mensah<sup>f</sup>, Camille Anoma<sup>i</sup>, Amadou Koné<sup>j</sup>, Diallo Dramane<sup>j</sup>, Hortense Fayé-  
10 Ketté<sup>k</sup>, Alain Yeo<sup>k</sup>, Bintou Dembélé Keita<sup>l</sup>, Christian Laurent<sup>c</sup>, Tania Crucitti<sup>m</sup>, for the  
11 CohMSM-PrEP study group

12 **Affiliations:**

13 <sup>a</sup> Institute of Tropical Medicine, Department of Clinical Sciences, Antwerp, Belgium

14 <sup>b</sup> Institute of Tropical Medicine, Department of Public Health, Antwerp, Belgium

15 <sup>c</sup> IRD, Inserm, Univ Montpellier, TransVIHMI, Montpellier, France

16 <sup>d</sup> CHU-SO-LNR-TB, Lomé, Togo

17 <sup>e</sup> LNR-TB, Ouagadougou, Burkina Faso

18 <sup>f</sup> Espoir Vie Togo, Lomé, Togo

19 <sup>g</sup> Association African Solidarité, Ouagadougou, Burkina Faso

20 <sup>h</sup> Institut National de Santé Publique, Centre Muraz, Bobo Dioulasso, Burkina Faso

21 <sup>i</sup> Espace Confiance, Abidjan, Côte d'Ivoire

22 <sup>j</sup> SEREFO/UCRC, USTTB, Bamako, Mali

23 <sup>k</sup> Institut Pasteur Côte d'Ivoire, Abidjan, Côte d'Ivoire

24 <sup>l</sup> ARCAD-SIDA, Bamako, Mali

25 <sup>m</sup> Centre Pasteur du Cameroun, Yaoundé, Cameroon

26 **Contact information**

27 Irith De Baetselier

28 Nationalestraat 155, 2000 Antwerp, Belgium

29 Tel: +3232476544

30 Fax: +3232470789

31 Email: [idebaetselier@itg.be](mailto:idebaetselier@itg.be)

32 **Keywords**

33 Sexually transmitted infections, Africa, pooling, pre-exposure prophylaxis, men who

34 have sex with men

35

36 **Abstract**

37 **Background:** Men who have sex with Men (MSM) using Pre-exposure prophylaxis  
38 (PrEP) are at risk for Sexually Transmitted Infections (STIs). Therefore, PrEP  
39 services should include regular screening for *Chlamydia trachomatis* (CT) and  
40 *Neisseria gonorrhoeae* (NG) at urethra, anorectum and pharynx. However, financial  
41 and logistic challenges arise in low resource settings. We assessed a new STI  
42 sample pooling method using the GeneXpert instrument among MSM initiating PrEP  
43 in West-Africa.

44 **Methods:** Urine, anorectal and pharyngeal samples were pooled per individual for  
45 analysis. Unpooled samples were analyzed in case of an invalid or positive result of  
46 the pool, to identify the infection's biological location. The results of two different  
47 pooling strategies were compared against a gold standard.

48 **Results:** We found a prevalence of 14.5% for chlamydia and 11.5% for gonorrhoea,  
49 with a predominance of infections being extra-genital (77.6%). The majority of  
50 infections were asymptomatic (88.2%). The pooling strategy with unpooling of invalid  
51 results only, had a sensitivity, specificity and agreement for CT of 95.4%, 98.7% and  
52 0.93, respectively; and 92.3%, 99.2% and 0.93 with additional unpooling of positive  
53 results. For NG, these figures were 88.9%, 97.7% and 0.85 for testing of invalid  
54 results, and 88.9%, 96.7% and 0.81 with unpooling of positive results.

55 **Conclusion:** West-African MSM have a high prevalence of extra-genital and  
56 asymptomatic STIs. The GeneXpert method provides an opportunity to move from  
57 syndromic towards etiological STI diagnosis in low income countries, as the platform  
58 is available in all African countries for tuberculosis testing. Pooling will reduce costs  
59 of triple site testing.

## 60 Introduction

61 The incidence of Sexually Transmitted Infections (STIs), including *Chlamydia*  
62 *trachomatis* (CT) and *Neisseria gonorrhoeae* (NG), is increasing globally. Their  
63 burden is disproportionately higher in low- and middle-income countries (LMIC) and in  
64 key populations, such as men who have sex with men (MSM) [1]. Fast detection and  
65 treatment of STIs is essential, as they raise serious health concerns, including  
66 increased risk of acquiring HIV infection [2].

67 UNAIDS recommends a combination strategy of biomedical, behavioral, and  
68 structural approaches for HIV prevention [3]. The use of Pre-exposure prophylaxis  
69 (PrEP) is an effective new biomedical HIV prevention tool, which is increasingly used  
70 among MSM in many high-resource countries [4,5]. However, PrEP may lead to a  
71 decrease in condom use and hence enhance STIs [6]. Indeed, PrEP demonstration  
72 studies among MSM in high-resource settings reported a high STI prevalence and  
73 incidence whereby most of the STIs were of extra-genital origin i.e. pharynx and  
74 anorectum. These STIs are frequently asymptomatic [7–11].

75 Although frequent screening of STIs among MSM in high-resource settings is  
76 currently debated [12], African MSM often report sexual relations with women. This  
77 sexual behavior may contribute to the spread of STIs to the general population.  
78 Hence, fast detection and treatment of STI infections is recommended in this  
79 population [13].

80 The World Health Organization (WHO) therefore advocates the integration of STI  
81 testing and treatment in all PrEP services, so that populations at risk have access to  
82 both STI prevention and care [14]. Furthermore, triple-site testing is recommended in  
83 MSM [15,16].

84 To date, nucleic acid amplification tests (NAATs) are the recommended diagnostic  
85 methods to detect STIs due to their high sensitivity and specificity. However, this  
86 method requires a state-of-the-art molecular laboratory and highly trained laboratory  
87 technicians [17,18]. Unfortunately, the screening of STIs using NAATs is hampered  
88 or even absent in LMIC due to the lack of adequate laboratory services and limited  
89 resources. Because of these barriers, LMIC use a syndromic approach for the  
90 diagnosis and treatment of symptomatic STIs.

91 The GeneXpert platform (Cepheid, Sunnyvale, US) holds promise as a method to  
92 detect STIs in LMIC. This platform is a molecular assay which requires minimal  
93 training and yields results within two hours. Since 2010, the WHO has recommended  
94 the use of the GeneXpert platform for the confirmation of tuberculosis and the  
95 detection of rifampicin resistance of *Mycobacterium tuberculosis*. As a consequence,  
96 the GeneXpert platform has become widely available throughout Africa [19]. In 2012,  
97 the Food and Drug Administration approved a GeneXpert cartridge to simultaneously  
98 detect CT/NG in genital samples and, quite recently, to test samples of pharyngeal  
99 and anorectal origin [20]. However, the high cost of the GeneXpert CT/NG cartridge  
100 hinders its utilization for the diagnosis of CT/NG in Africa.

101 In addition, testing one genital (urine) and two extra-genital samples (anorectal and  
102 pharyngeal) for STI screening in MSM will further increase this cost. Hence, pooling  
103 of the three collected samples per individual offers potential cost-savings in CT/NG  
104 detection in MSM presenting for PrEP [21]. Several pooling methods are described,  
105 including two using the GeneXpert instrument for STI detection [21–25]. To our  
106 knowledge, none of these pooling methods have been implemented in LMIC. In  
107 addition, very few are able to determine the biological location of the infection, which  
108 could be important for treatment and surveillance purposes.

109 We evaluated the performance of a new pooling method using the GeneXpert  
110 platform for the detection of CT and NG among MSM initiating PrEP in four West-  
111 African countries.

112 This article was submitted to an online preprint archive [26].

## 113 **Materials and Methods**

### 114 **Study setting**

115 The CohMSM-PrEP study is being conducted in four sites in West-Africa:  
116 Ouagadougou, Burkina Faso; Lomé, Togo; Bamako, Mali and Abidjan, Côte d'Ivoire.  
117 Its aim is to assess the feasibility of PrEP among a cohort of 500 MSM, including STI  
118 prevalence. Samples for CT/NG testing were collected from all participants at their  
119 initiation visit and transported to research laboratories (SEREFO, Bamako and  
120 Institut Pasteur, Abidjan) or to national reference laboratories for tuberculosis  
121 (Laboratoire National de Recherche sur la Tuberculose-TB, Ouagadougou and CHU-  
122 SO-LNR-TB, Lomé) where the GeneXpert instrument was available (hereafter called  
123 local STI laboratory).

124 The study has been approved by all applicable Ethics Committees and all  
125 participants provided written informed consent.

### 126 **Quality Control**

127 The STI reference laboratory of the Institute of Tropical Medicine (ITM) in Antwerp,  
128 Belgium, ensured the reliability and quality of the results of the local STI laboratories,  
129 including compliance with Good Clinical and Laboratory Practice Standards. This  
130 laboratory provided hands-on training in sample collection, processing, and storage  
131 at study initiation in each site. An external quality control (EQC) panel was tested at

132 study initiation and quarterly during the study. If DNA contamination was suspected,  
133 an environmental control of the laminar flow, bench, pipettes and the surface of the  
134 GeneXpert instrument was done.

### 135 **Laboratory methods**

136 Participants provided first-void urine and a physician took two pharyngeal and two  
137 anorectal samples (Eswab™, Copan Diagnostics, Brescia, Italy). After collection,  
138 samples were stored refrigerated (2-8°C) or frozen (-20°C) on site depending on the  
139 time of transport to the local STI laboratory (2-8°C<48h<-20°C). Transport of samples  
140 was performed under temperature monitored conditions using a cool box and cooling  
141 elements. Upon sample receipt in the local STI laboratory, one aliquot (1 mL) of  
142 urine, one anorectal and one pharyngeal Eswab™ (both randomly chosen from the  
143 duplicates) were immediately frozen (-20°C) until shipment on dry ice to ITM for  
144 reference testing. Samples for local testing were stored refrigerated (2-8°C) if  
145 analysis was performed within 72 hours of collection, otherwise, samples were stored  
146 frozen (-20°C).

#### 147 *Pooling method*

148 At the local STI laboratory a volume of 400 µL of the three samples (urine, anorectal  
149 and pharyngeal sample) per participant was transferred in a microtube (hereafter  
150 called pool). After vortexing, one mL of the pool was transferred into the CT/NG Xpert  
151 cartridge. When the result of the pool was negative, all samples were considered  
152 negative and were not individually tested. When the pool was positive or invalid,  
153 individual samples were tested as follows: 400 µL of one sample was added to 800  
154 µL diluted Phosphate Buffered Saline (hereafter called unpooling). After vortexing,

155 one mL was transferred into the cartridge and analyzed. Sample processing was  
156 performed in a laminar flow cabinet.

### 157 *Gold standard test algorithm*

158 All duplicate samples were tested individually at ITM according to the following test  
159 algorithm in place: CT/NG was detected using the Abbott RealTime (RT) CT/NG  
160 assay (Abbott Molecular, Des Plaines, Illinois, USA) according to the manufacturer's  
161 instructions. DNA extracts of positive samples were tested by in-house real time  
162 (RT)-PCR assays for CT and/or NG, both based on previously published primer sets  
163 [27,28]. The in-house RT-PCR for CT was able to differentiate L-type from non-L  
164 types. A sample was considered positive when positive in both the Abbott and the in-  
165 house RT-PCR. An initial positive Abbott assay result followed by a negative  
166 confirmatory NAAT result was defined as 'not confirmed'. Inhibition according to the  
167 Abbott assay was defined as 'inhibition'.

168 To exclude for sampling errors and confirm the quality of the sample, the presence of  
169 human material in the duplicate sample tested at ITM was assessed using a human  
170 Endogenous Retrovirus-3 PCR (ERV-3) on anorectal and pharyngeal samples that  
171 were solely positive on site [29].

### 172 **Identification and validation of the two pooling strategies**

173 Two different on-site pooling strategies were evaluated. Strategy 1 consisted of triple-  
174 site pooling and testing, and unpooling only when the pooled sample result was  
175 invalid. Strategy 2 consisted of triple-site pooling and testing, and unpooling when the  
176 pooled sample result was invalid or positive for either CT or NG.

177 The result of the two strategies was compared with the infection status according to  
178 the gold standard. A participant was defined as not infected when his three samples  
179 were all negative according to the gold standard. A participant was defined as  
180 infected if at least one sample was positive. In the event that one or more sampling  
181 site(s) were not confirmed and the other sampling site(s) were negative, the  
182 participant infection status was defined as not confirmed.

### 183 **Statistical analysis**

184 The sensitivity, specificity, positive predictive value, negative predictive value, with  
185 95% confidence intervals (CI) were calculated for strategies 1 and 2, excluding  
186 inhibited and not confirmed infection status. In addition, agreement of both strategies  
187 with the gold standard test algorithm was assessed by the Cohen's kappa statistic.

188 All analyses were performed in STATA V15.0.

### 189 **Cost analysis**

190 The costs of the two different screening strategies were compared against triple-site  
191 testing using the GeneXpert. The obtained prevalence of CT/NG in this study was  
192 used to simulate the costs of STI testing in a population of 500 MSM. An invalid rate  
193 of 4% was assumed.

194

## 195 **Results**

### 196 **Patient characteristics, test results and prevalence of CT/NG**

197 The ITM received baseline samples from 503 CohMSM-PrEP study participants.  
198 However, since the pooling method was not performed on 6 participants' samples,  
199 samples from 497 participants were included in the analysis.

200 All participants were MSM, with a median age of 24years (Inter Quartile Range: 22-  
201 28).

### 202 *Prevalence of STIs according to the gold standard algorithm*

203 According to the gold standard test algorithm performed at ITM, the study population  
204 had a prevalence of 14.5% CT (72/497), 11.5% NG (57/497) and 22.1% CT or NG  
205 (110/497). The anorectal site was the most common infected with CT or NG (n=76;  
206 60.8%); followed by the urethra (n=28; 22.4%) and pharynx (n=21; 16.8%). Two  
207 participants were positive in two biological sites for CT and eleven for NG. All  
208 confirmed CT positive samples were non-L genotypes.

209 Of the 110 infected participants, 97 of them (88.2%) reported no symptoms of STI.

### 210 *Test results at the study sites*

211 Using pooled samples 131 participants were positive for CT or NG: 21 had a mixed  
212 CT/NG infection; 71 were solely CT-infected; and 39 solely NG-infected. A total of  
213 353 participants tested negative and were not further investigated. An invalid result  
214 was obtained in 13 participants.

215 Using strategy 1, four additional NG infected participants were detected by unpooling  
216 the pools with an invalid result.

217 Using strategy 2, individual testing of the pooled samples with invalid or positive  
218 results decreased the number of infected participants with CT or NG to 128: 26 with a  
219 dual CT/NG infection, 60 with CT only and 42 with NG only.

220 The CT/NG results obtained on site (pooled and unpooling samples) and the results  
221 obtained at ITM are available in Figure S1.

## 222 **Test and sample quality**

223 The study sites participated in a quarterly EQC: one NG positive sample was missed;  
224 no false positive results were reported.

225 The number of samples positive for CT/NG, whatever the biological site, at the study  
226 sites was systematically higher as compared to the numbers found at ITM (Fig S1).  
227 One environmental check revealed the contamination of the GeneXpert instrument's  
228 surface with CT at one site. The contamination is probably the cause of overreporting  
229 CT in this site. Another site had a large number of falsely detected NG, however,  
230 contamination with NG was not detected during the quarterly EQC assessments and  
231 the environmental check.

232 The presence of human DNA was assessed in 43/46 individual extra-genital samples  
233 and in 11 (9 anorectal and 2 pharyngeal) (25.6%) of them human DNA was not  
234 detected.

## 235 **Performance of the two pooling strategies using the GeneXpert method**

236 Samples from the CT contaminated site collected after 31/08/2018 were excluded  
237 from statistical analyses, which limited the number of participants to 448. The  
238 Supplementary Material documents all discordant cases (table S1 and table S2).

239 The evaluation of the two pooling strategies using the GeneXpert against the gold  
240 standard for CT and NG is presented in Tables 1 and 2.

### 241 *Chlamydia trachomatis*

242 According to strategy 1, three CT were missed, resulting in a sensitivity of 95.4%.  
243 The Abbott delta cycle (DC) values (difference in cycle numbers between the cut-off

244 control and the sample cycle number) of the individual specimens from two  
 245 discordant pools were low, which correlates with a low target concentration. CT was  
 246 falsely detected on site in five participants (specificity 98.7%). Applying strategy 2,

ORGANISM			GOLD STANDARD TEST ALGORITHM			
			POSITIVE	NEGATIVE	NOT CONFIRMED	TOTAL
<b>CHLAMYDIA</b>	<b>STRATEGY 1</b>	GENEXPERT POSITIVE	62	5	3	70
		GENEXPERT NEGATIVE	3	372	3	378
		TOTAL	65	377	6	448
<b>TRACHOMATIS</b>	<b>STRATEGY 2</b>	GENEXPERT POSITIVE	60	3	3	66
		GENEXPERT NEGATIVE	5	374	3	382
		TOTAL	65	377	6	448
<b>NEISSERIA</b>	<b>STRATEGY 1</b>	GENEXPERT POSITIVE	48	9	3	60
		GENEXPERT NEGATIVE	6	381	1	388
		TOTAL	54	390	4	448
<b>GONORRHOEAE</b>	<b>STRATEGY 2</b>	GENEXPERT POSITIVE	48	13	3	64
		GENEXPERT NEGATIVE	6	377	1	384
		TOTAL	54	390	4	448

247 the sensitivity decreased to 92.3% and the specificity increased to 99.2%.

248 Table 1: Comparison of the two test strategies to detect *Chlamydia trachomatis* and  
 249 *Neisseria gonorrhoeae*.

250 Strategy 1 will only test the samples individually when the pooled sample result was invalid.

251 Strategy 2 will test the samples individually when the pooled sample result was invalid or  
 252 positive for either CT or NG. The discordant samples are explained in detail in the

253 Supplementary material (Table S1 and Table S2).

	<b>SENSITIVITY</b>	<b>SPECIFICITY</b>	<b>PPV</b>	<b>NPV</b>	<b>%</b>	<b>K-</b>	
	<b>% (95% CI)</b>	<b>% (95% CI)</b>	<b>% (95% CI)</b>	<b>% (95% CI)</b>	<b>AGREEMENT</b>	<b>COEFF</b>	
<b>CHLAMYDIA</b>	<b>STRATEGY 1</b>	95.4%	98.7%	92.5%	99.2%	98.2%	0.93
	<b>(unpooling of INV)</b>	(87.1-99.0)	(96.9-99.6)	(83.8-96.7)	(97.6-99.7)		
	<b>STRATEGY 2</b>	92.3%	99.2%	95.2%	98.7%	98.2%	0.93
	<b>(unpooling of INV &amp; POS)</b>	(83.0-97.5)	(97.7-99.8)	(86.7-99.0)	(97.0-99.6)		
<b>GONORRHEA</b>	<b>STRATEGY 1</b>	88.9%	97.7%	84.2%	98.5%	96.6%	0.85
	<b>(unpooling of INV)</b>	(77.4-95.8)	(95.7-98.9)	(73.5-91.1)	(96.8-99.3)		
	<b>STRATEGY 2</b>	88.9%	96.7%	78.7%	98.4%	95.7%	0.81
	<b>(unpooling of INV &amp; POS)</b>	(77.4-95.8)	(94.4-98.2)	(66.2-86.4)	(96.7-99.3)		

254 Table 2: Evaluation of the two pooling strategies against the gold standard algorithm for either

255 *Chlamydia trachomatis* and *Neisseria gonorrhoeae*.

256 *INV: invalid; POS: positive; PPV: Positive Predictive Value; NPV: Negative Predictive Value; K-*

257 *coeff: Kappa-coefficient; CI: Confidence Interval*

258 *Neisseria gonorrhoeae*

259 Six NG infections were missed with strategy 1, yielding a sensitivity of 88.9%. The

260 Abbott DC values for the individual specimens included in the six pools indicated a high

261 bacterial load.

262 Using strategy 1, nine samples were positive but not confirmed by the gold standard  
 263 algorithm (specificity 97.7%). When applying the second strategy, one sample was  
 264 actually negative, however, five additional tests were positive, almost all from one study  
 265 site, suggesting a possible DNA contamination (specificity of 96.7%).

## 266 Cost analysis

267 A prevalence of 22% CT/NG, as found in this study, was assumed. Compared to triple  
 268 testing, a 56% decrease in costs was noted with strategy one and 30% with strategy  
 269 two (Table 3).

STI screening strategies	Number of participants	Calculation of number of tests required	Total number of tests	Assay cost (19 USD per test)	Cost per infection
<b>Triple site testing</b>	500	Every site of sampling = $500 * 3$	1500	28.500 USD	220 USD
<b>Pooling strategy 1</b>	500	500 pooled samples = 500 individual testing of 20 invalid results = $20*3$	560	10.640 USD	97 USD
<b>Pooling strategy 2</b>	500	500 pooled samples = 500 individual testing of 20 invalid results = $20*3$ individual testing of 110 positive results = $110*3$	890	16910 USD	154 USD

270 Table 3: Number of tests required according different strategies and cost simulation using a  
 271 combined prevalence of CT/NG of 22%

272

## 273 Discussion

274 We are among the first to report on the prevalence of chlamydia and gonorrhea in MSM  
275 initiating PrEP in West-Africa. The data indicate a high prevalence of chlamydia (14.5%)  
276 and gonorrhea (11.5%), mainly in asymptomatic (88.2%) individuals. These  
277 asymptomatic infections would not have been treated according to the syndromic  
278 approach, which is currently the standard of care in LMIC. In addition, 77.6% of  
279 infections were extra-genital. These findings reinforce the recommendation that STI  
280 services, including triple-site testing, should be integrated in PrEP programs in LMIC.  
281 Therefore, we aimed to implement an STI screening strategy using the GeneXpert  
282 instrument as its availability throughout Africa will facilitate STI testing. The Xpert  
283 CT/NG assay is now put forward as a potential point-of-care assay for STI detection in  
284 remote health-care settings as it is easy, robust, and has very high analytical  
285 performance [30–32]. Previous studies showed that this technology is acceptable in  
286 identifying STIs among Sub-Saharan African young women, however, to date, no study  
287 has been performed among African MSM [32–37].

288 We used a new pooling method with the GeneXpert platform to screen for STIs in  
289 genital and extra-genital samples among MSM. Although the pooling method was  
290 designed as such to identify the origin of infection, we showed that there is no clinical  
291 utility. First of all, we did not detect a single case of Lymphogranuloma venereum (LGV)  
292 in our study population. LGV is frequently detected in European MSM and requires a  
293 three week treatment with doxycycline versus one week in the event of a regular  
294 chlamydia infection. Secondly, all antimicrobials recommended nowadays for the  
295 treatment of gonorrhea are equally effective in the three biological sites [19,20,38].

296 Furthermore, the performance of the pooling method did not improve when unpooling  
297 positive samples. Nevertheless, we favor keeping the possibility to test the individual  
298 samples in case of an invalid pooled sample result to avoid additional sample collection  
299 and subsequent delay in result reporting.

300 Applying strategy one resulted in nine participants not receiving treatment (9/448;  
301 2.0%), and 14 participants receiving unnecessary treatment (14/448; 3.1%). The  
302 number of false positives increased to 16 for the individually tested samples, mainly  
303 caused by a probable contamination of *Neisseria gonorrhoeae* at one of the sites. We  
304 also report on a CT DNA contamination of the GeneXpert instrument's surface at  
305 another site. The GeneXpert method is a closed system that reduces contamination to  
306 an absolute minimum, however, due to its very low lower limit of detection, the assay is  
307 more prone to target contamination caused by the presence of genetic targets in the  
308 work environment or by sample cross contamination.

309 Although the GeneXpert CT/NG assay can be integrated into remote healthcare  
310 settings, this apparent risk of contamination may lead to erroneous results, which may  
311 cause emotional distress, stigma and unnecessary antibiotic pressure. Therefore, we  
312 strongly recommend that detection of CT/NG using the GeneXpert instrument is  
313 performed under the supervision of qualified laboratory personnel.

314 This is, to our knowledge, the first study reporting on a sample pooling method among a  
315 large number of African MSM initiating PrEP. Other pooling methods in MSM have been  
316 published, including methods using the GeneXpert assay [23–26]. Speers and  
317 colleagues evaluated a pooling method using the GeneXpert versus single site testing

318 using the Cobas 4800 CT/NG assay and found an excellent agreement for NG and a  
319 substantial one for CT [26]. Our pooling method scored better for CT than NG and is in  
320 accordance with the findings of Sultan *et al.* who also found a decreased sensitivity of  
321 NG detection in pooled samples [25].

322 There are some differences between the two GeneXpert pooling studies. Speers *et al.*  
323 added the anorectal and pharyngeal swab directly to the GeneXpert Urine Specimen  
324 Kit, limiting manipulations [26]. We opted to work with simple urine containers and  
325 Eswabs™ and to prepare a separate pool to identify the biological origin of infection.

326 Using Eswabs™, our pooling method can tackle one of the most important global health  
327 priorities set forward by the WHO, namely the surveillance for antimicrobial resistance  
328 of NG [39]. Future research will need to show if surveillance for AMR of NG using  
329 Eswabs™ can be implemented in LMIC.

330 The present study does, however, have several limitations which may explain the  
331 discordances other than target contamination. Firstly, sampling errors: we determined  
332 the presence of human DNA in the pharyngeal and anorectal samples in samples that  
333 were positive solely using the GeneXpert. One quarter of them lacked human material  
334 in the duplicate sample, although physicians were trained in sample collection in order  
335 to avoid sampling errors [23]. This could also explain the false negative pools.  
336 Secondly, the Xpert CT/NG assay can detect as little as 10 NG genome copies per  
337 reaction [32]. We cannot exclude the idea that some of the positive NG results solely  
338 obtained with the GeneXpert were truly low positive results not detectable by the gold  
339 standard. Finally, samples tested with the gold standard algorithm underwent an

340 additional freeze-thawing cycle which may have impaired the DNA in low concentration  
341 samples.

342 In conclusion, we showed that MSM initiating PrEP in Africa have high prevalence rates  
343 of extra-genital and asymptomatic STIs and that African countries can perform an  
344 etiological diagnosis of STIs without implementing specialized NAATs.

345 The availability of PrEP in LMIC is a unique opportunity to strengthen STI services in  
346 high risk populations. The momentum is now to move to efficient STI screening and to  
347 limit onward transmission. In this new PrEP-era, the WHO, ministries of health and  
348 stakeholders at a global level will need to ensure that STI management is integrated in  
349 PrEP services, and negotiations with companies to provide the tests at affordable prices  
350 are, therefore, essential.

351

## 352 Funding

353 This work was supported by Expertise France (Initiative 5%) and France Recherche  
354 Nord & Sud Sida-hiv Hépatites (ANRS 12369). Cepheid provided the Xpert CT/NG  
355 cartridges according to the HBDC program.

## 356 Acknowledgements

357 We would like to thank all the participants, study and laboratory staff of the CohMSM-  
358 PrEP study. We would also like to thank Wendy Thijs for the data entry and Margaux  
359 Balduck for additional review of the figure and tables.

## 360 Potential conflicts of interest

361 No reported conflicts of interest.

## 362 References

- 363 1. World Health Organization. Report on global sexually transmitted infection  
364 surveillance 2018. **2019**; Available at:  
365 <https://www.who.int/reproductivehealth/publications/stis-surveillance-2018/en/>.  
366 Accessed 6 May 2019.
- 367 2. Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV  
368 transmission. *Nat Rev Microbiol* **2004**; 2:33–42.
- 369 3. UNAIDS. Global AIDS update **2019** — Communities at the centre. Jt United  
370 Nations Program HIV/AIDS **2019**; Available at:  
371 [https://www.unaids.org/sites/default/files/media\\_asset/2019-global-AIDS-](https://www.unaids.org/sites/default/files/media_asset/2019-global-AIDS-update_en.pdf)  
372 [update\\_en.pdf](https://www.unaids.org/sites/default/files/media_asset/2019-global-AIDS-update_en.pdf). Accessed 10 September 2019.
- 373 4. Chen Y-HH, Guigayoma J, McFarland W, Snowden JM, Raymond HF. Increases  
374 in Pre-exposure Prophylaxis Use and Decreases in Condom Use: Behavioral  
375 Patterns Among HIV-Negative San Francisco Men Who have Sex with Men,  
376 2004–2017. *AIDS Behav* **2019**; 23:1841–1845.
- 377 5. Cáceres CF, Borquez A, Klausner JD, Baggaley R, Beyrer C. Implementation of  
378 pre-exposure prophylaxis for human immunodeficiency virus infection: progress  
379 and emerging issues in research and policy. *J Int AIDS Soc* **2016**; 19:21108.
- 380 6. Ramchandani MS, Golden MR. Confronting Rising STIs in the Era of PrEP and  
381 Treatment as Prevention. *Curr HIV/AIDS Rep* **2019**; 16:244–256.
- 382 7. Reyniers T, Nöstlinger C, Laga M, De Baetselier I, Crucitti T, Wouters K,  
383 Smekens B, Buyze J, Vuylsteke B.. Choosing between daily and event-driven

- 384 Pre-Exposure Prophylaxis: results of a Belgian PrEP demonstration project. *J*  
385 *Acquir Immune Defic Syndr* **2018**;79:186–194
- 386 8. Hoornenborg E, Coyer L, Achterbergh RCA, Matser A, Schim van der Loeff MF,  
387 Boyd A, van Duijnhoven YTHP, Bruisten S, Oostvogel P, Davidovich U,  
388 Hogewoning A, Prins M, de Vries HJC. Sexual behaviour and incidence of HIV  
389 and sexually transmitted infections among men who have sex with men using  
390 daily and event-driven pre-exposure prophylaxis in AMPrEP: 2 year results from a  
391 demonstration study. *Lancet HIV* **2019**; 6:e447–e455.
- 392 9. Traeger MW, Cornelisse VJ, Asselin J, Price B, Roth NJ, Willcox J, Tee BK,  
393 Fairley CK, Chang CC, Armishaw J, Vujovic O, Penn M, Cundill P, Forgan-Smith  
394 G, Gall J, Pickett C, Lal L, Mak A, Spelman TD, Nguyen L, Murphy DA, Ryan KE,  
395 El-Hayek C, West M, Ruth S, Batrouney C, Lockwood JT, Hoy JF, Hellard ME,  
396 Stoové MA, Wright EJ, PrEPX Study Team.. Association of HIV Preexposure  
397 Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals  
398 at High Risk of HIV Infection. *JAMA* **2019**; 321:1380.
- 399 10. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, Sullivan AK,  
400 Clarke A, Reeves I, Schembri G, Mackie N, Bowman C, Lacey CJ, Apea V, Brady  
401 M, Fox J, Taylor S, Antonucci S, Khoo SH, Rooney J, Nardone A, Fisher M,  
402 McOwan A, Phillips AN, Johnson AM, Gazzard B, Gill ON. Pre-exposure  
403 prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness  
404 results from the pilot phase of a pragmatic open-label randomised trial. *Lancet*  
405 (London, England) **2015**; 387:53–60.

- 406 11. Vuylsteke B, Reyniers T, De Baetselier I, Nöstlinger C, Crucitti T, Buyze J,  
407 Kenyon C, Wouters K, Laga M. Daily and event-driven pre-exposure prophylaxis  
408 for men who have sex with men in Belgium: results of a prospective cohort  
409 measuring adherence, sexual behaviour and STI incidence. *J Int AIDS Soc* **2019**;  
410 22.
- 411 12. Kenyon C. Toward a Set of Criteria to Decide Which STIs to Screen for in PrEP  
412 Cohorts. *Front public Heal* **2019**; 7:154.
- 413 13. Adedimeji A, Sinayobye J d'Amour, Asiimwe-Kateera B, Chaudhry J, Buzinge L,  
414 Gitembagara A, Murenzi G, Mugenzi P, Patel V V, Castle PE, Mutesa L, Palefsky  
415 J, Anastos KM. Social contexts as mediator of risk behaviors in Rwandan men  
416 who have sex with men (MSM): Implications for HIV and STI transmission. *PLoS*  
417 *One* **2019**; 14:e0211099.
- 418 14. World Health Organization. Prevention and control of sexually transmitted  
419 infections (STIs) in the era of oral pre-exposure prophylaxis (PrEP) for HIV. **2019**.  
420 Available at <https://www.who.int/hiv/pub/prep/prevention-sti-prep/en/>. Accessed  
421 01 October 2019.
- 422 15. Centers for Disease Control and Prevention: US Public Health Service:  
423 Preexposure prophylaxis for the prevention of HIV infection in the United States—  
424 **2017** Update: a clinical practice guideline. Availabl at:  
425 <https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf>. Accessed:  
426 10 September 2019.
- 427 16. World Health Orgoanization. Guideline on when to start antiretroviral therapy and

- 428 on pre-exposure prophylaxis for HIV. **2015**. Available at:  
429 <http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/>. Accessed 3 August  
430 2019.
- 431 17. Bignell C, Unemo M, Radcliffe K, Jensen JS, Babayan K, Barton S, Cusini M,  
432 Gomberg M, Janier M, Khotenashvili L, Moi H, Neumann M, Patel R, Ross J,  
433 Sherrard J, Tiplica G-S, Unemo M, Van De Laar M, Van Der W. 2012 European  
434 guideline on the diagnosis and treatment of gonorrhoea in adults. *Int J STD AIDS*  
435 **2013**; 24:85–92.
- 436 18. Lanjouw E, Ouburg S, de Vries H, Stary A, Radcliffe K, Unemo M. 2015 European  
437 guideline on the management of *Chlamydia trachomatis* infections. *Int J STD*  
438 *AIDS* **2016**; 27:333–348.
- 439 19. World Health Organization. WHO monitoring of Xpert MTB/RIF roll-out. **2016**;  
440 Available at: <http://apps.who.int/tb/laboratory/xpertmap/>. Accessed 13 August  
441 2019.
- 442 20. Food and Drug Administration. FDA clears first diagnostic tests for extragenital  
443 testing for chlamydia and gonorrhea. Available at: [https://www.fda.gov/news-](https://www.fda.gov/news-events/press-announcements/fda-clears-first-diagnostic-tests-extragenital-testing-chlamydia-and-gonorrhea)  
444 [events/press-announcements/fda-clears-first-diagnostic-tests-extragenital-testing-](https://www.fda.gov/news-events/press-announcements/fda-clears-first-diagnostic-tests-extragenital-testing-chlamydia-and-gonorrhea)  
445 [chlamydia-and-gonorrhea](https://www.fda.gov/news-events/press-announcements/fda-clears-first-diagnostic-tests-extragenital-testing-chlamydia-and-gonorrhea). Accessed 5 August 2019.
- 446 21. De Baetselier I, Osbak KK, Smet H, Kenyon CR, Crucitti T. Take three, test one: a  
447 cross-sectional study to evaluate the molecular detection of *Chlamydia*  
448 *trachomatis* and *Neisseria gonorrhoeae* in pooled pharyngeal, anorectal and urine  
449 samples versus single-site testing among men who have sex with men in

- 450 Belgium. *Acta Clin Belg* **2018**; :1–5.
- 451 22. Thielemans E, Wyndham-Thomas C, Henrard S, De Vleeschouwer A, Steensels  
452 D, Montesinos I, Debaisieux L, Delforge M-L, Van Vooren J-P, Goffard J-C.  
453 Screening for Chlamydia trachomatis and Neisseria gonorrhoeae Infections in  
454 Men Who Have Sex With Men: Diagnostic Accuracy of Nucleic Acid Amplification  
455 Test on Pooled Urine, Anorectal, and Pharyngeal Specimens. *Sex Transm Dis*  
456 **2018**; 45:195–198.
- 457 23. Sultan B, White JA, Fish R, Carrick G, Brima N, Copas A, Robinson A, Gilson R,  
458 Mercey D, Benn P. The ‘3 in 1’ Study: Pooling Self-Taken Pharyngeal, Urethral,  
459 and Rectal Samples into a Single Sample for Analysis for Detection of Neisseria  
460 gonorrhoeae and Chlamydia trachomatis in Men Who Have Sex with Men. *J Clin*  
461 *Microbiol* **2016**; 54:650–6.
- 462 24. Speers DJ, Chua I-LJLJ, Manuel J, Marshall L. Detection of Neisseria  
463 gonorrhoeae and Chlamydia trachomatis from pooled rectal, pharyngeal and urine  
464 specimens in men who have sex with men. *Sex Transm Infect* **2018**; 94:293–297.
- 465 25. Roosen G, Baclet V, Alcaraz I, Huleux T, Senneville E, Patoz P, Blondiaux N.  
466 2015. Journées Nationales de formation des paramédicaux en infectiologie. Abstr  
467 PADS02-08.
- 468 26. De Baetselier I, Vuylsteke B, Yaya I, Dagnra A, Souba D, Yaka J, Kadanga G,  
469 Traore I, Cuylaerts V, Smet H, Dah ETT, Mensah E, Anoma C, Kone A, Faye-  
470 Kette H, Yeo A, Dembele B, Laurent C, Crucitti T. 2020. To pool or not to pool  
471 samples for Sexually Transmitted Infections detection in Men who have Sex with

- 472 Men? An evaluation of a new pooling method using the GeneXpert instrument in  
473 West-Africa. medRxiv 2020.01.22.20017392.
- 474 27. Chen C-Y, Chi KH, Alexander S, Ison CA, Ballard RC. A real-time quadriplex PCR  
475 assay for the diagnosis of rectal lymphogranuloma venereum and non-  
476 lymphogranuloma venereum Chlamydia trachomatis infections. Sex Transm Infect  
477 **2008**; 84:273–6.
- 478 28. Hopkins MJ, Ashton LJ, Alloba F, Alawattegama A, Hart IJ. Validation of a  
479 laboratory-developed real-time PCR protocol for detection of Chlamydia  
480 trachomatis and Neisseria gonorrhoeae in urine. Sex Transm Infect **2010**;  
481 86:207–11.
- 482 29. Yuan CC, Miley W, Waters D. A quantification of human cells using an ERV-3 real  
483 time PCR assay. J Virol Methods **2001**; 91:109–17.
- 484 30. Causer LM, Guy RJ, Tabrizi SN, Whiley DM, Speers DJ, Ward J, Tangey A,  
485 Badman SG, Hengel B, Natoli LJ, Anderson DA, Wand H, Wilson D, Regan DG,  
486 Shephard M, Donovan B, Fairley CK, Kaldor JM. Molecular test for chlamydia and  
487 gonorrhoea used at point of care in remote primary healthcare settings: a  
488 diagnostic test evaluation. Sex Transm Infect **2018**; 94:340–345.
- 489 31. Natoli L, Guy RJ, Shephard M, Causer L, Badman SG, Hengel B, Tangey A,  
490 Ward J, Coburn T, Anderson D, Kaldor J, Maher L, TTANGO Investigators. “I Do  
491 Feel Like a Scientist at Times”: A Qualitative Study of the Acceptability of  
492 Molecular Point-Of-Care Testing for Chlamydia and Gonorrhoea to Primary Care  
493 Professionals in a Remote High STI Burden Setting. PLoS One **2015**;

494 10:e0145993.

495 32. Jacobsson S, Boiko I, Golparian D, Blondeel K, Kiarie J, Toskin I, Peeling RW,  
496 Unemo M. WHO laboratory validation of Xpert® CT/NG and Xpert® TV on the  
497 GeneXpert system verifies high performances. *APMIS* **2018**; 126:907–912.

498 33. Tabrizi SN, Unemo M, Golparian D, Twin J, Limnios AE, Lahra M, Guy R.  
499 Analytical Evaluation of GeneXpert CT/NG, the First Genetic Point-of-Care Assay  
500 for Simultaneous Detection of *Neisseria gonorrhoeae* and *Chlamydia trachomatis*.  
501 *J Clin Microbiol* **2013**; 51:1945–1947.

502 34. Gaydos CA, Van Der Pol B, Jett-Goheen M, Barnes M, Quinn N, Clark C, Daniel  
503 GE, Dixon PB, Hook EW, CT/NG Study Group. Performance of the Cepheid  
504 CT/NG Xpert Rapid PCR Test for Detection of *Chlamydia trachomatis* and  
505 *Neisseria gonorrhoeae*. *J Clin Microbiol* **2013**; 51:1666–72.

506 35. Wynn A, Ramogola-Masire D, Gaolebale P, Moshashane N, Sickboy O, Duque S,  
507 Williams E, Doherty K, Klausner JD, Morroni C. Prevalence and treatment  
508 outcomes of routine *Chlamydia trachomatis*, *Neisseria gonorrhoeae* and  
509 *Trichomonas vaginalis* testing during antenatal care, Gaborone, Botswana. *Sex*  
510 *Transm Infect* **2018**; 94:230–235.

511 36. Verwijs MC, Agaba SK, Sumanyi J-CC, Umulisa MM, Mwambarangwe L,  
512 Musengamana V, Uwineza M, Cuylaerts V, Crucitti T, Jespers V, van de Wijgert  
513 JHHMHM. Targeted point-of-care testing compared with syndromic management  
514 of urogenital infections in women (WISH): a cross-sectional screening and  
515 diagnostic accuracy study. *Lancet Infect Dis* **2019**; 19:658–669.

- 516 37. Garrett N, Mitchev N, Osman F, Naidoo J, Dorward J, Singh R, Ngobese H,  
517 Rompalo A, Mlisana K, Mindel A. Diagnostic accuracy of the Xpert CT/NG and  
518 OSOM Trichomonas Rapid assays for point-of-care STI testing among young  
519 women in South Africa: a cross-sectional study. *BMJ Open* **2019**; 9:e026888.
- 520 38. World Health Organization. WHO guidelines for the treatment of chlamydia  
521 trachomatis. **2016** Available at:  
522 [https://apps.who.int/iris/bitstream/handle/10665/246165/9789241549714-](https://apps.who.int/iris/bitstream/handle/10665/246165/9789241549714-eng.pdf?sequence=1)  
523 [eng.pdf?sequence=1](https://apps.who.int/iris/bitstream/handle/10665/246165/9789241549714-eng.pdf?sequence=1). Accessed 02 October 2019.
- 524 39. World Health Organization. Global Health Sector Strategy on Sexually  
525 Transmitted Infections 2016-2021. *WHO* **2016**; 1:63. Available at:  
526 <https://www.who.int/reproductivehealth/publications/rtis/ghss-stis/en/>. Accessed  
527 10 September 2019
- 528



530

531

532